Switching chemotherapy in patients with borderline or locally advanced pancreatic ductal adenocarcinoma (PDAC) improved outcomes in a retrospective study conducted at Mayo Clinic. Patients who did not respond to first-line therapy had substitutions that ultimately were beneficial to a majority, according to the researchers.
“More than half of these patients subsequently showed response that allowed proceeding to curative-intent surgical resection,” said lead study author Lavanya
MAY 11, 2018